Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: Past and present

Expert Opinion on Investigational Drugs

Volumn 23, Issue 3, 2014, Pages 295-304

  Casimiro, Mathew C ^a,b   Velasco Velázquez, Marco ^c   Aguirre Alvarado, Charmina ^c   Pestell, Richard G ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Cancer; CDK inhibitors; Cyclin D1; Cyclin dependent kinase

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84894211810     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.867017     Document Type: Review

References (126)

1. Johnson LN. The regulation of protein phosphorylation. Biochem Soc Trans 2009;37:627-41
2. Hunter T. Why nature chose phosphate to modify proteins. Philos Trans R Soc Lond B Biol Sci 2012;367:2513-16
3. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177-83
4. Baselga J. Targeting tyrosine kinases in cancer: The second wave. Science 2006;312:1175-8
5. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 2009;9:153-66
6. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005;30:630-41
7. Sherr CJ. G1 phase progression: Cycling on cue. Cell 1994;79:551-5
8. Lolli G, Johnson LN. CAK-Cyclin-dependent Activating Kinase: A key kinase in cell cycle control and a target for drugs? Cell Cycle 2005;4:572-7
9. Harper JW, Elledge SJ. The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev 1998;12:285-9
10. Harbour JW, Dean DC. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev 2000;14:2393-409
11. Harbour JW, Luo RX, Dei Santi A, et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999;98:859-69
12. Russell A, Thompson MA, Hendley J, et al. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 1999;18:1983-91
13. Zhou BB, Elledge SJ. The DNA damage response: Putting checkpoints in perspective. Nature 2000;408:433-9
14. Chen Y, Poon RY. The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front Biosci 2008;13:5016-29
15. Vousden KH, Prives C. Blinded by the light: The growing complexity of p53. Cell 2009;137:413-31
16. Blagden SP, Glover DM. Polar expeditions-provisioning the centrosome for mitosis. Nat Cell Biol 2003;5:505-11
17. Fukasawa K. Centrosome amplification, chromosome instability and cancer development. Cancer Lett 2005;230:6-19
18. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009;460:278-82
19. Takai N, Hamanaka R, Yoshimatsu J, et al. Polo-like kinases (Plks) and cancer. Oncogene 2005;24:287-91
20. Brittle AL, Ohkura H. Centrosome maturation: Aurora lights the way to the poles. Curr Biol 2005;15:R880-2
21. Okuda M. The role of nucleophosmin in centrosome duplication. Oncogene 2002;21:6170-4
22. Lindqvist A, Rodriguez-Bravo V, Medema RH. The decision to enter mitosis: Feedback and redundancy in the mitotic entry network. J Cell Biol 2009;185:193-202
23. van Leuken R, Clijsters L, Wolthuis R. To cell cycle, swing the APC/C. Biochim Biophys Acta 2008;1786:49-59
24. Fisher RP. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 2005;118:5171-80
25. Phatnani HP, Greenleaf AL. Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev 2006;20:2922-36
26. Egloff S, Murphy S. Cracking the RNA polymerase II CTD code. Trends Genet 2008;24:280-8
27. Wang C, Pattabiraman N, Zhou JN, et al. Cyclin D1 repression of peroxisome proliferator-Activated receptor gamma expression and transactivation. Mol Cell Biol 2003;23:6159-73
28. Sicinski P, Donaher JL, Parker SB, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995;82:621-30
29. Evron E, Umbricht CB, Korz D, et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001;61:2782-7
30. Sicinski P, Donaher JL, Geng Y, et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 1996;384:470-4
31. Sicinska E, Aifantis I, Le Cam L, et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 2003;4:451-61
32. Sankaran VG, Ludwig LS, Sicinska E, et al. Cyclin D3 coordinates the cell cycle during differentiation to regulate erythrocyte size and number. Genes Dev 2012;26:2075-87
33. Pestell RG. New roles of cyclin D1. Am J Pathol 2013;183:3-9
34. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991;350:512-15
35. Tsujimoto Y, Yunis J, Onorato-Showe L, et al. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t (11;14) chromosome translocation. Science 1984;224:1403-6
36. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-8
37. Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-17
38. Dickson C, Fantl V, Gillett C, et al. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 1995;90:43-50
39. Naidu R, Wahab NA, Yadav MM, et al. Expression and amplification of cyclin D1 in primary breast carcinomas: Relationship with histopathological types and clinico-pathological parameters. Oncol Rep 2002;9:409-16
40. Bieche I, Olivi M, Nogues C, et al. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 2002;86:580-6
41. Hosokawa Y, Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: Analysis of allele-specific expression. Genes Chromosomes Cancer 1998;22:66-71
42. Benzeno S, Lu F, Guo M, et al. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. Oncogene 2006;25:6291-303
43. Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511
44. Mittal MK, Singh K, Misra S, et al. SLUG-induced elevation of D1 cyclin in breast cancer cells through the inhibition of its ubiquitination. J Biol Chem 2011;286:469-79
45. Hattori H, Zhang X, Jia Y, et al. RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells. Blood 2007;110:640-50
46. Wang W, Yang L, Hu L, et al. Inhibition of UBE2D3 expression attenuates radiosensitivity of MCF-7 human breast cancer cells by increasing hTERT expression and activity. PLoS One 2013;8:e64660
47. Maeda I, Ohta T, Koizumi H, et al. In vitro ubiquitination of cyclin D1 by ROC1-CUL1 and ROC1-CUL3. FEBS Lett 2001;494:181-5
48. Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinasepRb-controlled G1 checkpoint. Mol Cell Biol 1996;16:6917-25
49. Fantl V, Stamp G, Andrews A, et al. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995;9:2364-72
50. Dowdy SF, Hinds PW, Louie K, et al. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993;73:499-511
51. Hinds PW, Dowdy SF, Eaton EN, et al. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994;91:709-13
52. Hinds PW, Mittnacht S, Dulic V, et al. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992;70:993-1006
53. Liu J-J, Chao J-R, Jiang M-C, et al. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH3T3 cells. Mol Cell Biol 1995;15:3654-63
54. Lee RJ, Albanese C, Fu M, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 2000;20:672-83
55. Lee RJ, Watanabe G, Albanese C, et al. Regulation of cyclin D1 by the Neu, cerbB2, proto-oncogene. Proc. Annu Meet Am. Assoc. Cancer Res; 1998
56. Robles AI, Rodriguez-Puebla ML, Glick AB, et al. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 1998;12:2469-74
57. Wang TC, Cardiff RD, Zukerberg L, et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-71
58. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-21
59. Rowlands TM, Pechenkina IV, Hatsell SJ, et al. Dissecting the roles of beta-catenin and cyclin D1 during mammary development and neoplasia. Proc Natl Acad Sci USA 2003;100:11400-5
60. Reddy HK, Mettus RV, Rane SG, et al. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res 2005;65:10174-8
61. Landis MW, Pawlyk BS, Li T, et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006;9:13-22
62. Baker GL, Landis MW, Hinds PW. Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle 2005;4:330-8
63. Li Z, Jiao X, Wang C, et al. Cyclin D1 induction of cellular migration requires p27(KIP1). Cancer Res 2006;66:9986-94
64. Li Z, Wang C, Jiao X, et al. Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem 2008;283:7007-15
65. Jeselsohn R, Brown NE, Arendt L, et al. Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell 2010;17:65-76
66. Choi YJ, Li X, Hydbring P, et al. The requirement for cyclin d function in tumor maintenance. Cancer Cell 2012;22:438-51
67. Rosenberg CL, Motokura T, Kronenberg HM, et al. Coding sequence of the overexpressed transcript of the putative oncogene PRAD1/cyclin D1 in two primary human tumors. Oncogene 1993;8:519-21
68. Neumeister P, Pixley FJ, Xiong Y, et al. Cyclin D1 governs adhesion and motility of macrophages. Mol Biol Cell 2003;14:2005-15
69. Holnthoner W, Pillinger M, Groger M, et al. Fibroblast growth factor-2 induces Lef/Tcf-dependent transcription in human endothelial cells. J Biol Chem 2002;277:45847-53
70. Casimiro MC, Wang C, Li Z, et al. Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol 2013;27:1415-28
71. Casimiro MC, Crosariol M, Loro E, et al. ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest 2012;122:833-43
72. Friedl P, Wolf K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer 2003;3:362-74
73. Friedl P, Alexander S. Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 2011;147:992-1009
74. Li Z, Wang C, Jiao X, et al. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 2006;26:4240-56
75. LaBaer J, Garrett MD, Stevenson LF, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997;11:847-62
76. Cheng M, Olivier P, Diehl JA, et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999;18:1571-83
77. Alt JR, Gladden AB, Diehl JA. p21 (Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem 2002;277:8517-23
78. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12
79. Besson A, Gurian-West M, Schmidt A, et al. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004;18:862-76
80. Li Z, Jiao X, Wang C, et al. Alternative cyclin d1 splice forms differentially regulate the DNA damage response. Cancer Res 2010;70:8802-11
81. Jirawatnotai S, Hu Y, Michowski W, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011;474:230-4
82. Hagen KR, Zeng X, Tucker-Kahn S, et al. Inhibition of Cdk4 radiosensitizes breast cancer cells by increasing PP2A levels, and decreasing Bad136 phosphorylation [abstract 1467]. In AACR 103rd Annual Meeting 2012; Mar 31 - Apr 4 2012; American Association for Cancer Research, Chicago, IL
83. Bakhoum SF, Compton DA. Chromosomal instability and cancer: A complex relationship with therapeutic potential. J Clin Invest 2012;122:1138-43
84. Holland AJ, Cleveland DW. Losing balance: The origin and impact of aneuploidy in cancer. EMBO Rep 2012;13:501-14
85. Oyama T, Kashiwabara K, Yoshimoto K, et al. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res 1998;58:2876-80
86. van Diest PJ, Michalides RJ, Jannink L, et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 1997;150:705-11
87. Shoker BS, Jarvis C, Davies MP, et al. Immunodetectable cyclin D(1)is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions. Br J Cancer 2001;84:1064-9
88. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from nonmalignant lesions. Nat Med 1995;1:1257-60
89. Nelsen CJ, Kuriyama R, Hirsch B, et al. Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem 2005;280:768-76
90. Evers DL, Breitenbach JM, Borysko KZ, et al. Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d] pyrimidines does not correlate with antiviral activity. Antimicrob Agents Chemother 2002;46:2470-6
91. Vesely J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994;224:771-86
92. Boutis A, Papazisis K, Pistevou-Gompaki K, et al. Cyclin-dependent kinase (CDK) inhibitor olomoucine enhances gamma-irradiation-induced apoptosis and cell cycle arrest in Raji cells. Anticancer Res 2006;26:3493-8
93. Moravec J, Krystof V, Hanus J, et al. 2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors. Bioorg Med Chem Lett 2003;13:2993-6
94. Al-Issa SA. Synthesis of a new series of pyridine and fused pyridine derivatives. Molecules 2012;17:10902-15
95. Knockaert M, Gray N, Damiens E, et al. Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised inhibitors. Chem Biol 2000;7:411-22
96. Hardcastle IR, Arris CE, Bentley J, et al. N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2. J Med Chem 2004;47:3710-22
97. Usui T, Ban HS, Kawada J, et al. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. Bioorg Med Chem Lett 2008;18:285-8
98. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38
99. Ibrahim DA, Ismail NS. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as antiproliferative CDK2 inhibitors. Eur J Med Chem 2011;46:5825-32
100. Sun Y, Li YX, Wu HJ, et al. Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells. J Cancer 2011;2:36-51
101. Eastman A, Kohn EA, Brown MK, et al. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: Similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol Cancer Ther 2002;1:1067-78
102. Misra RN, Xiao HY, Williams DK, et al. Synthesis and biological activity of Naryl-2-Aminothiazoles: Potent pan inhibitors of cyclin-dependent kinases. Bioorg Med Chem Lett 2004;14:2973-7
103. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-66
104. Wesierska-Gadek J, Maurer M, Zulehner N, et al. Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol 2011;226:341-9
105. Malumbres M, Pevarello P, Barbacid M, et al. CDK inhibitors in cancer therapy: What is next? Trends Pharmacol Sci 2008;29:16-21
106. Blachly JS, Byrd JC. Emerging drug profile: Cyclin-dependent kinase inhibitors. Leuk Lymphoma 2013;54:2133-43
107. Sedlacek H, Czech J, Naik R, et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996;9:1143-68
108. Parker BW, Kaur G, Nieves-Neira W, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91:458-65
109. Wyatt PG, Woodhead AJ, Berdini V, et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1Hpyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 2008;51:4986-99
110. Squires MS, Feltell RE, Wallis NG, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclindependent kinases, in human tumor cell lines. Mol Cancer Ther 2009;8:324-32
111. Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010;9:2344-53
112. Feldmann G, Mishra A, Bisht S, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 2011;12:598-609
113. Fu W, Sharma SS, Ma L, et al. Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor. Cell Death Dis 2013;4:e566
114. Desai BM, Villanueva J, Nguyen TT, et al. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One 2013;8:e59588
115. Gorlick R, Kolb EA, Houghton PJ, et al. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer 2012;59:1266-74
116. Nemunaitis JJ, Small KA, Kirschmeier P, et al. A first-in-human, phase 1, doseescalation study of dinaciclib, a novel cyclindependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 2013;11:259
117. Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/ 6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptorpositive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77
118. Michaud K, Solomon DA, Oermann E, et al. Pharmacologic inhibition of cyclindependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010;70:3228-38
119. Katsumi Y, Iehara T,MiyachiM, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun 2011;413:62-8
120. Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012;104:476-87
121. Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011;104:1862-8
122. Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/ 6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18:568-76
123. Rader JA, Hart L, Russell M, et al. CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas. In 104th Annual Meeting of the American Association for Cancer Research; AACR, Philadelphia (PA), Washington, DC: 2013
124. Zhang Y, Sicinska E, Moss S, et al. Human liposarcoma growth inhibition by novel CDK4/6 inhibitor LEE011. In AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; AACR, Philadelphia (PA), San Francisco, CA: 2011
125. Gelbert LM, Cai S, Lin X, et al. Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/ 6) with broad in vivo antitumor activity. In AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; AACR, Philadelphia (PA), San Francisco, CA: 2011
126. Sanchez-Martinez C, Gelbert LM, Shannon H, et al. LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts. In AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; AACR, Philadelphia (PA), San Francisco, CA: 2011